Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

3472 - Applicability of the Lung Immune Prognostic Index (LIPI) to metastatic Triple negative Breast Cancer (mTNBC) patients treated with Immune Checkpoint Targeted Monoclonal Antibodies (ICT mAbs)

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Presenters

Aurore Vozy

Citation

Annals of Oncology (2018) 29 (suppl_8): viii90-viii121. 10.1093/annonc/mdy272

Authors

A. Vozy1, A. Simonaggio1, E. Auclin2, L. Mezquita Pérez3, C. Baldini1, P. Martin-Romano1, B. Pistilli4, A. Gazzah1, R. Bahleda1, V. Ribrag1, S. Postel-Vinay1, S. Champiat1, J. Soria5, F. André4, C. Massard1, B. Besse3, S. Delaloge4, A. Varga1

Author affiliations

  • 1 Ditep, Gustave Roussy Institut de Cancérologie, 94805 - Villejuif/FR
  • 2 Oncology, Hopital European George Pompidou, 75015 - Paris/FR
  • 3 Dept Of Cancer Medicine, Gustave Roussy Institut de Cancérologie, 94805 - Villejuif/FR
  • 4 Breast Cancer Unit, Department Of Medical Oncology, Gustave Roussy - Cancer Campus, 94805 - Villejuif/FR
  • 5 Ditep, Medimmune, 20878 - Gaithersburg/US
More

Resources

Abstract 3472

Background

Tumor-infiltrating lymphocytes are prognostic and predictive in TNBC. However, the level of activity of Immune Checkpoint Targeted Monoclonal Antibodies (ICT mAbs) remains low in this indication and biomarkers are needed to select for patients who could benefit from these treatments. Pretreatment LIPI, based on derived NLR (dNLR = neutrophils/[leucocytes-neutrophils]) and lactate dehydrogenase (LDH) assessment has been associated with outcomes for ICT mAbs in advanced NSCLC patients. We tested whether LIPI has the same impact on mTNBC patients’ outcome.

Methods

Biological and clinical data were retrospectively collected from mTNBC patients treated with ICT mAbs between Jan 2014 & Apr 2018 in our Drug Development Department. Three LIPI risk groups were studied: good (dNLR<3 & LDH3 or LDH>ULN), poor (dNLR>3 & LDH>ULN). The primary endpoint was progression-free survival (PFS) and the secondary endpoint was overall survival (OS).

Results

Forty-two patients were included with a median age of 45, 48% were ECOG 0 and the median prior chemotherapy lines was 3. Twenty-one percent of patients received a PD1/PD-L1 inhibitor as monotherapy, 79% had ICT mAbs combination. The median PFS and OS under ICT mAbs was 1.35 months (IC 95% 1.27; 2.93) and 13.5 months (5.9; not reached) respectively according to RECIST v1.1. LIPI classified 18 patients as good (43%), 18 patients (43%) as intermediate and 6 patients (14%) as poor risk group. Median PFS was 2.65, 1.32 and 0.85 months for good (GP), intermediate (IP) and poor prognosis (PP) respectively (P = 0.002). Median OS was 18.10 months for GP, 9.8 months for IP and 1.6 months PP (P = <0.0001). Metastatic cutaneous lesions were also associated with poor PFS with ICT mAbs in our cohort, HR 3.189, P = 0.0028. The PDL1 status does not seem to influence LIPI risk groups.

Conclusions

Applying baseline LIPI in mTNBC patients is feasible and is correlated with ICT mAbs outcomes for this population. A larger retrospective validation cohort is being evaluated and more data will be available for the ESMO presentation.

Clinical trial identification

Legal entity responsible for the study

Varga Andréa.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

J-C. Soria: Full time employee: MedImmune AstraZeneca since September 2017. C. Massard: Amgen, Astellas, Astra Zeneca, Bayer, Celgene, Genentech, Ipsen, Janssen, Lilly, Novartis, Pfizer, Roche, Sanofi, Orion. B. Besse: AstraZeneca, BMS, Boehringer-Ingelheim, Lilly, Pfizer, Roche-Genentech, Sanofi-Aventis, Servier, Onxeo, OncoMed, Inivata, OSE Pharma, Loxo. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.